Pfizer Takes A Hit On US Oncology Biosimilars In Q1
Lower Net Prices Take A Bite Out Of Firm’s First-Quarter Biosimilars Turnover
Executive Summary
Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing pressures took their toll.